Oceanside, California USA, Apr 16 – AOTI Inc. announced today the 10,000th patient has been treated with its revolutionary patented Topical Wound Oxygen Therapy.
“This is a momentous milestone for our company and a testament to the clinical efficacy of TWO2 therapy, we are delighted to have helped heal the wounds of so many patients and look forward to even greater adoption of TWO2 therapy in the future” stated Dr. Mike Griffiths, CEO and President of AOTI.
“We are pleased that healthcare professionals around the world are recognizing more and more the clinical benefits of adding Topical Wound Oxygen (TWO2) therapy to existing wound care best practices, that by helping completely heal chronic wounds will greatly reduce the total cost of care, but more importantly improve the patient’s quality of life”, added Griffiths.
About AOTI
AOTI Inc. is a leading international company providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closing Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Oceanside, California USA and Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net
